Design Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2025 and 2024

Balance Sheets

(in thousands, except share and par value data)

	December 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$16,856	$22,563
Investment securities	202,989	222,914
Prepaid expenses and other current assets	3,939	2,563
Total current assets	223,784	248,040
Property and equipment, net	981	1,410
Right-of-use asset, related party	1,438	2,216
Other assets	—	427
Total assets	$226,203	$252,093
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,312	$2,186
Accrued expenses and other current liabilities (including related party amounts of $890 and $800, respectively)	10,743	6,276
Total current liabilities	13,055	8,462
Operating lease liability, net, related party	645	1,534
Total liabilities	13,700	9,996
Commitments and contingencies (See Note 11)
Stockholders' equity:
Common stock: $0.0001 par value; 200,000,000 shares authorized, 60,398,051 and 56,754,341 shares issued and outstanding at December 31, 2025 and 2024, respectively	6	6
Additional paid-in capital	509,100	468,830
Accumulated deficit	(297,006)	(227,214)
Accumulated other comprehensive income	403	475
Total stockholders' equity	212,503	242,097
Total liabilities and stockholders' equity	$226,203	$252,093

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.